Anika Therapeutics | ANIK - Capital Y Las Reservas





Capital Y Las Reservas Cambio Fecha
Abbott USD 52.13B 1.3B 2025-12
Agenus USD -271.11M 3.03M 2025-12
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Anika Therapeutics USD 143.46M 3.34M 2025-12
Arrowhead Research USD 568.42M 102.37M 2025-12
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Insmed USD 738.98M 206.6M 2025-12
Integra LifeSciences USD 1.04B 5.89M 2025-12
Intrexon USD 43.17M 75.33M 2024-06
J&J USD 78.47B 0 2025-09
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
MacroGenics USD 55.59M 11.41M 2025-12
Merit Medical Systems USD 1.58B 54.9M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 71.71B 1.55B 2025-12
Smith & Nephew USD 5.54B 331M 2025-12
Stryker USD 21.78B 594M 2025-09
Surmodics USD 111.31M 7.59M 2025-06
Veracyte USD 1.26B 36.61M 2025-09
Xencor USD 635.59M 10.27M 2025-12
Zimmer Biomet Holdings USD 12.7B 68.3M 2025-12